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Objectives The aim of this study was to describe hospital variation and factors associated with adherence to guidelines for
implantable cardioverter-defibrillator (ICD) therapy.
Background Studies have shown incomplete application of ICD therapy in eligible heart failure (HF) patients.
Methods New or discharge prescription rates for ICD therapy (ejection fraction 30% without documented ICD contraindi-
cations) for hospitals were calculated from participants in the GWTG-HF (Get With The Guidelines–Heart Failure)
registry during January 2005 to June 2007. With hierarchical modeling, hospitals’ patient case-mix adjusted ICD
rate and hospital factors associated with ICD use were determined. The association of ICD rate and other quality
of care indicators and procedure use was determined.
Results Overall use of ICD in-hospital or planned implantation rate was 20%. This rate ranged widely among hospitals,
from 1% among the lowest tertile to 35% among the top tertile (p  0.01). After adjusting for patient case mix,
independent hospital characteristics associated with higher ICD use were percutaneous coronary intervention,
coronary artery bypass grafting, and heart transplant capability as well as larger hospital bed size (p  0.01).
Hospital Centers for Medicare and Medicaid Services/Joint Commission on the Accreditation of Healthcare Orga-
nizations performance measures (discharge instructions, angiotensin-converting enzyme inhibitor/angiotensin II
receptor blocker use, smoking cessation; p  0.05) were similar across ICD, whereas higher ICD-rate hospitals
had higher adherence to GWTG-HF performance measures (beta-blocker use, evidence-based beta-blocker use,
aldosterone-antagonist, hydralazine/nitrate; p 0.05) except warfarin in patients with atrial fibrillation (p  0.18).
Conclusions There is significant unexplained hospital variation in the use of ICD therapy among potentially eligible HF patients.
However, hospitals that use ICD therapy more often also have more rapidly adopted other newer evidence-based HF
therapies. (J Am Coll Cardiol 2009;53:416–22) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.045S
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ccepted September 29, 2008.everal clinical trials have shown that implantable
ardioverter-defibrillators (ICDs) reduce mortality in
atients with a low left ventricular ejection fraction
LVEF) (1,2). Thus, the 2005 American College of
See page 423
ardiology/American Heart Association (ACC/AHA)
uidelines assign a Class I indication for ICD therapy in
atients with an LVEF 30% and symptomatic heart
ailure (HF) receiving optimal medical therapy (3). De-
pite these guidelines, recent studies have highlighted the
ncomplete adoption of ICD therapy, including significant
isparities by race and sex (4,5).
r
m
r
o
b
r
d
i
I
(
M
D
q
a
t
h
a
w
c
a
i
a
m
i
c
H
i
t
R
a
o
e
i
f
n
t
p
v
a
r
e
R
a
p
w
r
c
m
t
S
w
b
L
w
m
c
a
t
t
p
f
H
e
o
c
o
c
[
w
S
m
p
t
I
c
w
p
s
t
W
t
h
c
t
p
m
l
w
c
M
c
W
c
t
p
v
h
h
d
e
p
i
i
m
n
d
l
417JACC Vol. 53, No. 5, 2009 Shah et al.
February 3, 2009:416–22 Hospital Variation in ICD UseReasons for the inconsistent and disparate use of guideline-
ecommended ICD therapy are unclear and might differ from
edical pharmacotherapy. Barriers to medical therapy usually
elate to knowledge, preferences, and biases among providers
r patients (6). Although device therapy likely has similar
arriers, other important limitations might exist. Hospitals
equire highly skilled professionals and technical facilities to
eliver device therapies. To understand these issues, we exam-
ned hospital-level variation and characteristics associated with
CD therapy use in eligible HF patients in the GWTG-HF
Get With The Guidelines–Heart Failure) registry.
ethods
ata source. The GWTG-HF registry is a voluntary
uality improvement initiative started in 2005 to enhance
dherence to practice guidelines in hospitalized HF pa-
ients. The design and validity of this program’s methods
ave been published previously (7–11). Briefly, clinical data
re abstracted for patients admitted with HF in compliance
ith the Joint Commission on the Accreditation of Health-
are Organizations (JCAHO) and Centers for Medicare
nd Medicaid Services (CMS) standards. With standard-
zed definitions, variables collected include demographic
nd clinical characteristics, medical history, previous treat-
ents, contraindications to evidence-based therapies, and
n-hospital outcomes (8,9). Hospital data elements are
ollected for all enrolling hospitals from the American
ospital Association database (12). Data collection regard-
ng ICD therapy includes prior implantation, new implan-
ation, or planned implantation after hospital discharge.
easons and contraindications for not placing an ICD are
lso collected: not receiving optimal medical therapy, recent
nset HF, acute myocardial infarction within prior 40 days,
conomic, social, religious, compliance, a life-threatening
llness that would compromise 1-year survival with good
unctional status, other contraindications, or other factors
oted by the patient. Data quality is monitored via elec-
ronic data checks, and generated reports assure the com-
leteness and accuracy of the submitted data. Only sites and
ariables with a high degree of completeness are used in
nalyses. All data were collected with an interactive case
eport form and patient management tool (Outcome Sci-
nces, Inc., Cambridge, Massachusetts). The Duke Clinical
esearch Institute served as the data analysis center and
nalyzed the aggregate de-identified data for research pur-
oses. All participating institutions were required to comply
ith local regulatory guidelines with their local institutional
eview board’s approval of the GWTG-HF protocol. Be-
ause data are used primarily locally for quality improve-
ent, sites were granted a waiver of informed consent under
he common rule.
tudy population. We confined the analysis to patients
ho met Class I recommendations for ICD therapy on the
asis of the 2005 ACC/AHA HF guidelines, including an
VEF 30%, at the time of data collection (3). Patients tere excluded if they had docu-
ented reasons for not placing or
ontraindications to ICD ther-
py as described in the preceding
ext. Patients were excluded from
he primary analysis if they had a
rior ICD in place or were trans-
erred in from another hospital.
ospitals enrolling 10 ICD-
ligible patients or hospitals with-
ut any reported procedures (i.e.,
oronary angiography, percutane-
us coronary intervention [PCI],
oronary artery bypass grafting
CABG], or cardiac transplant)
ere excluded.
tatistical analysis. The pri-
ary outcome measure was the
lacement of ICD during hospi-
al stay or documented plans for
CD implantation after dis-
harge among eligible patients
ith LVEF 30% without a
rior ICD. For univariate analy-
es, hospitals were divided into
ertiles, on the basis of rates of ICD use in eligible patients.
e examined characteristics of hospitals capable of ICD
herapy defined as at least 1 ICD procedure compared with
ospitals without any implantations. At the patient level, we
ompared between the 2 hospital types the use of medical
herapy, other cardiac procedures, the CMS/JCAHO (13)
erformance measures, and GWTG-HF Clinical Perfor-
ance Measures (14) according to ACC/AHA HF guide-
ines. Cochran-Mantel-Haenszel row-mean scores tests
ere used to compare the trend of the adherence rates and
ategorical baseline characteristics variables, and Cochran-
antel-Haenszel nonzero correlation tests were used for
omparing the continuous variables among the tertiles.
ilcoxon rank-sum test and chi-square tests were used to
ompare the continuous and categorical variables in hospi-
als with versus without ICD implantations, respectively.
Multivariable analysis with hierarchical model with hos-
ital random effects was performed to model ICD use
ariation among and between hospitals, adjusted for the
ospital’s patient case-mix, and calculate the adjusted
ospital-specific ICD rate. In ICD-eligible patients, the
egree of missing data was 6% for all the covariates,
xcept 7.5% for systolic blood pressure. Factors for which
 0.05 were removed from the model. The reduced model
ncluded age, sex, race (white, black, and other races),
nsurance status (Medicare, Medicaid, other [e.g., health
aintenance organization, Veteran’s Administration, and
o insurance]), systolic blood pressure, and comorbid con-
itions, including chronic renal failure, anemia, atrial fibril-
ation, cerebrovascular accident or transient ischemic at-
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
CABG  coronary artery
bypass grafting
CMS  Centers for
Medicare and Medicaid
Services
GWTG-HF  Get With The
Guidelines–Heart Failure
HF  heart failure
ICD  implantable
cardioverter-defibrillator
JCAHO  Joint Commission
on the Accreditation of
Healthcare Organizations
LV  left ventricular
LVEF  left ventricular
ejection fraction
PCI  percutaneous
coronary interventionack, chronic obstructive pulmonary disease, ischemic
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Hospital Variation in ICD Use February 3, 2009:416–22eart disease, depression, diabetes mellitus, hyperlipid-
mia, and renal insufficiency.
The hospital’s case-mix adjusted ICD rate was calculated
rom the reduced model with observed ICD rate in each
ospital divided by the hospital’s estimated expected ICD rate
nd then multiplied by the overall observed ICD rate. The
stimated expected rate was calculated as the hospital-specific
ean of the predicted probabilities of ICD use, adjusted for
he aforementioned covariates but without the site random
ffect. Then the hospitals’ adjusted ICD rates were compared
n each subgroup of hospitals according to teaching status;
apability of PCI, CABG, or transplant; bed size; and geo-
raphic location. Wilcoxon rank-sum and Kruskal-Wallis tests
ere used for comparison of adjusted ICD rates in 2 samples
nd regions, respectively. The Cochran-Mantel-Haenszel
onzero correlation test was used to compare the trend of
djusted ICD rates with bed size.
A p value 0.05 was considered statistically significant
or all tests. All analyses were performed with SAS software
ersion 8.2 (SAS Institute, Cary, North Carolina).
esults
nalysis cohort. From January 1, 2005, through June 26,
007, 54,750 HF patients were discharged from 234
WTG-HF hospitals. Six procedure-capable hospitals
ithout any procedures recorded and 94 hospitals with 10
CD-eligible patients were excluded. We also excluded
,545 of 12,693 patients with an ICD in place at the time
f the index HF hospital stay. The final analysis cohort
onsisted of 134 hospitals with 10,148 ICD-eligible
atients.
Figure 1 Rates of New or Planned ICD Therapy at GWTG-HF Ho
Hospital implantable cardioverter-defibrillator (ICD) rate  new or planned ICD
use/eligible heart failure (HF) patients. GWTG-HF  Get With The Guidelines–Hearospital ICD rates. The overall use of ICD therapy (new
r planned) at discharge was 20.0%. Figure 1 shows the
ospital-level variation in new or planned ICD therapy in
ligible patients without a prior ICD ranging from 0% to
0%, with a mean rate of 17.2%. The median rate was
1.6% with 25th and 75th interquartile ranges of 1.5% and
6.3%, respectively. Discharge of ICD therapy by hospital
ertiles of use was 35%, 12%, and 1% (p  0.001).
The highest ICD-rate hospitals were more likely to treat
hites and patients with hyperlipidemia and prior myocar-
ial infarction but were similar in their treatment of women
nd patients with other cardiac risk factors and comorbidi-
ies compared with low or medium ICD-rate hospitals
Table 1). High ICD-rate hospitals were also more likely to
rovide cardiac procedures (i.e., coronary angiography, PCI,
ABG, or transplant), have more beds, and have an
cademic affiliation than low or medium ICD-rate hospitals
Table 2). Hospital processes resulted in similar discharge
erformance measures across all 3 hospital volume catego-
ies, but high ICD-rate hospitals were more likely to meet
WTG-HF performance measures with the exception of
arfarin use in HF patients with atrial fibrillation than low
r medium ICD-rate hospitals (Table 3).
CD-capable versus non–ICD-capable hospitals. Analy-
is of hospitals with at least 1 implant versus none showed
ifferences in patient and hospital characteristics between these
ospitals. There were 28 hospitals with 874 patients without
ny ICD implants, and 106 hospitals with 9,274 patients with
t least 1 implant. Eligible patients presenting to ICD-capable
ospitals were more likely to be younger (age 66 years vs. 69
ears, p  0.001) and to be black (28% vs. 23%, p  0.001),
ls for Eligible HF Patients Without an ICD
e registry.spita
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February 3, 2009:416–22 Hospital Variation in ICD Useut these hospitals had similar frequencies in the treatment of
omen (36% for both, p 0.77) and patients with cardiac risk
actors and comorbid illnesses. The ICD-capable hospitals
ere larger (mean beds 416 vs. 210, p 0.001) and were more
ikely to have an academic affiliation (62% vs. 53%, p 0.001)
s well as were more likely to be capable of PCI (86% vs. 63%,
 0.001), CABG (75% vs. 38%, p  0.001), and cardiac
ransplants (15% vs. 0%, p  0.001). The hospitals were
imilar in meeting performance measures for HF patients, with
he exception of ICD-capable hospitals more likely providing
ldosterone antagonists, warfarin in patients with atrial fibril-
aseline Characteristics of ICD-Eligible HF Patients Among High-, M
Table 1 Baseline Characteristics of ICD-Eligible HF Patients Am
High ICD Use (n  4,500)
48 Hospitals
Patient characteristics
Age (yrs)* 68 (56, 78)
Female 34
Race
Black 22
White 67
Insurance
Medicare 49
Medicaid 6
Other 34
Atrial fibrillation 20
Diabetes mellitus 36
Hyperlipidemia 38
Hypertension 63
History of myocardial infarction 15
Peripheral vascular disease 10
History of stroke 11
Renal insufficiency† 15
Cigarette smoking 25
Procedures performed
Coronary angiography 16
Coronary artery bypass grafting 1.0
Percutaneous coronary intervention 1.2
Right heart catheterization 6.5
Heart transplant 0.02
eported as percentages. *Expressed as median (25th, 75th percentile). †Serum creatinine 2.0
HF  heart failure; ICD  implantable cardioverter-defibrillator.
omparison of Hospital Characteristics Among High-, Medium-, and
Table 2 Comparison of Hospital Characteristics Among High-, M
High ICD Use (n  4,500)
48 Hospitals
Med
Hospital size (beds)* 449 (334, 590)
Academic 68
Region
Northeast 16
Midwest 38
South 33
West 13
PCI capable 91
CABG capable 89
Heart transplant capable 23eported as percentages. *Expressed as median (25th, 75th percentile).
CABG  coronary artery bypass grafting; ICD  implantable cardioverter-defibrillator; PCI  percutaneation, evidence-based beta-blocker drugs, and lipid-lowering
gents at discharge (p  0.001) than non–ICD-capable
ospitals.
djusted hospital ICD rates. When adjusting ICD
ates for patient case mix, hospital characteristics associ-
ted with higher ICD use in eligible patients were heart
ransplant, PCI, and CABG capabilities as well as larger
ospital bed size and academic status (Fig. 2). Additional
nadjusted exploratory analysis at the hospital level
howed no statistical association of ICD use with private
ayer mix or percentage of blacks treated but a weak
m-, and Low-Volume ICD Hospitals
High-, Medium-, and Low-Volume ICD Hospitals
ium ICD Use (n  3,548)
42 Hospitals
Low ICD Use (n  2,100)
44 Hospitals p Value
69 (56, 79) 68 (55, 79) 0.44
38 36 0.03
0.001
33 32
56 55
0.001
45 51
9 7
36 27
22 21 0.32
38 37 0.09
32 30 0.001
66 64 0.004
9 11 0.001
9 9 0.25
11 10 0.83
14 14 0.66
23 28 0.03
12 6 0.001
0.4 0 0.001
1.2 0.14 0.001
3.7 1.1 0.001
0.08 0 0.93
l.
-Volume ICD Hospitals
m-, and Low-Volume ICD Hospitals
D Use (n  3,548)
2 Hospitals
Low ICD Use (n  2,100)
44 Hospitals p Value
3 (274, 527) 216 (128, 330) 0.001
59 52 0.001
0.001
26 26
20 13
31 45
20 11
88 61 0.001
79 23 0.001
10 2.6 0.001ediu
ong
MedLow
ediu
ium IC
4
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Hospital Variation in ICD Use February 3, 2009:416–22ssociation of higher ICD use as the percentage of
ninsured patients decreased (p  0.05).
iscussion
o our knowledge, this study is the first to describe hospital
ariation and hospital factors associated with ICD use in
dherence to CMS/JCAHO Performance Measures and GWTG-HF Pas d on ACC/AHA HF Guid lines Among High-, Medium-, and Low
Table 3 Adherence to CMS/JCAHO Performance Measures andBased on ACC/AHA HF Guidelines Among High-, Mediu
CMS/JCAHO performance measures
Patients discharged with 6 instructions*
Discharged with ACEI/ARB in patients with LV dysfunction
Patients with smoking history discharged with smoking cessation
Composite performance measures
Composite performance measure (successes/total eligible)†
Composite performance measure for 100% compliance
GWTG-HF performance improvement measures
Discharged with beta-blocker in patients with LV dysfunction
HF patients with atrial fibrillation discharged on warfarin
HF patients with LV dysfunction discharged on aldosterone antagonist
HF patients with LV dysfunction discharged on evidenced-based beta-blocker
(bisoprolol, carvedilol, metoprolol succinate)
Black HF patients discharged on hydralazine and isorbide dinitrate combination
HF patients discharged on lipid-lowering medication
HF patients with systolic BP 140 mm Hg and diastolic BP 90 mm Hg
HF patients with EF 30% with new ICD or discharged with ICD
eported as percentages. *Instructions at discharge for: activity level, diet, discharge medications
ACC American College of Cardiology; ACEI angiotensin-converting enzyme inhibitor; AHA Am
or Medicare and Medicaid Services/Joint Commission on the Accreditation of Healthcare Organizati
CD  implantable cardioverter-defibrillator; LV left ventricular.
Figure 2 Association of Case-Mix Adjusted Hospital ICD Use W
Represented by median rates and interquartile ranges. *p  0.05. CABG  coron
bypass grafting; ICD  implantable cardioverter-defibrillator; PCI  percutaneous cligible patients. Four important observations were noted in
ur study. First, overall ICD therapy remains low in eligible
atients with only one-fifth of potentially eligible patients
eceiving new implantations or prescription for implanta-
ion at discharge. Second, there is wide (35-fold) variation
f ICD therapy use in eligible patients in GWTG-HF
mance Measuree ICD Hospitals
G-HF Performance Measure
nd Low-Volume ICD Hospitals
High ICD Use
(n  4,500)
48 Hospitals
Medium ICD Use
(n  3,548)
42 Hospitals
Low ICD Use
(n  2,100)
44 Hospitals p Value
83 82 81 0.05
86 89 86 0.91
92 86 91 0.09
90 (18) 90 (17) 88 (19) 0.006
69 69 65 0.01
89 90 87 0.02
66 68 61 0.18
31 29 20 0.001
73 70 68 0.001
7 6 3 0.001
61 56 51 0.001
83 82 79 0.005
35 12 1 0.001
-up appointments, weight monitoring, and if symptoms are to worsen. †Expressed as mean (SD).
eart Association; ARB angiotensin II receptor blocker; BP blood pressure; CMS/JCAHO Centers
 ejection fraction; GWTG-HF  Get With The Guidelines–Heart Failure registry; HF  heart failure;
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February 3, 2009:416–22 Hospital Variation in ICD Useospitals. Third, important structural characteristics, such as
ospital size and procedural capabilities, are associated with
CD therapy use. Finally, the wide variation in ICD therapy
ersus narrower variation in performance measures of care
uggests that hospitals approach ICD guideline recommen-
ations differently from medical therapy, but higher ICD-
se hospitals are more likely to adopt newer HF therapies.
We found that the use of ICD therapy is associated with key
ospital characteristics—the presence of cardiovascular proce-
ure capabilities, academic affiliation, and a larger size. Fur-
hermore, ICD implantation rates are associated with higher
ates of other cardiac procedures, mirroring the findings of
rior studies examining the diffusion and variation of the use of
ther cardiac procedures, specifically PCI and CABG (15–17).
ther factors influencing ICD use might include the availabil-
ty of electrophysiologists and dedicated facilities. However,
apacity limitations should not affect discharge prescription of
CD therapy, but long wait times or difficulty getting timely
ollow-up in the appropriate clinic might deter referring
hysicians or patients.
Individual physician preferences and opinions regarding
CD therapy for chronic HF could also explain the wide
ariation in ICD rates in GWTG-HF hospitals. The lack of
iagnostic criteria beyond LVEF to stratify patients who
ight receive maximal benefit from ICD therapy might
ontribute to limited adoption of this technology. Cost
onsiderations might also play a role in the broader adoption
f ICD therapy. Furthermore, ICD use could be influenced
y recent public and physician concerns over the safety of
he devices (18,19). Additionally, the lag in dissemination of
linical trial data and guideline recommendation updates
nto broader clinical practice, particularly in the non-
ardiologist community, might explain the low rates of ICD
se in our cohort (6,20).
linical implications. Physicians’ reluctance to recom-
end ICD therapy underscores the difficulty to characterize
on chronic optimal medical therapy” as well as assessment
f symptomatic HF in the hospitalized setting (3). How-
ver, hospital systems with the infrastructure to perform other
ardiac procedures might be overzealous in defining a reason-
ble functional class or optimal medical therapy. Regardless of
he source of variation, these qualitative issues highlight the
ifficulty in establishing ICD therapy as a quality metric for
atients with chronic HF and should be considered before
ying device therapy metrics to reimbursement.
Although there was no significant variation in adherence
o CMS/JCAHO metrics, adherence to GWTG-HF per-
ormance measures—which includes HF therapies with
ore recent clinical evidence—was higher at ICD implant-
ng and high ICD-rate hospitals versus their counterparts.
his observation suggests that GWTG-HF hospitals with
igher rates of ICD use are overall more rapid adopters of
vidence-based therapies. Furthermore, early hospital
dopters of newer HF therapies seem to incorporate this
vidence more rapidly than their counterparts regardless of
nancial incentives. Future studies should investigate therocesses of these hospitals to understand how they more
apidly assimilate evidence-based therapies into routine
linical practice compared with their peers.
tudy limitations. First, the GWTG-HF initiative is a
egistry of patients hospitalized with decompensated HF,
hich could overestimate the number of patients eligible for
CD therapy. However, we confined the analysis to patients
ho would have qualified for ICD therapy before hospital stay
i.e., patients with a history of chronic HF and no documented
ontraindication to ICD therapy). Second, GWTG-HF
ight include hospitals with a higher likelihood of following
vidence-based recommendations, thus likely conveying a best-
ase scenario. Third, standardized reporting might have led to
nderreporting of contraindications to ICD therapy, and chart
eview might not have identified patients with anticipated
urvival of 1 year, unless explicitly stated by the charting
hysician. The variation observed might represent variation in
ocumentation of patient ineligibility for ICD placement or
ariation in documentation of post-discharge ICD placement
eferral. Fourth, although we controlled for insurance status,
ut-of-pocket expenses could affect patient decisions for ICD
herapy. Finally, because we have limited information about
he hospital characteristics, specialties of the caring physician,
nd the availability of electrophysiologists implanting these
evices, we can only make limited judgments on the resources
nd capabilities at each site for ICD implantation.
onclusions
n spite of ACC/AHA Class I guideline recommendations
or ICD use in patients with an LVEF 30% and symp-
omatic HF on optimal medical therapy, the variation in
CD use by GWTG-HF hospitals is wide, 0% to 80%, with
n overall ICD use of 20% in potentially eligible patients.
e identified hospital factors that could limit ICD use in
F patients among participating hospitals. Even though
ther challenges exist in the guideline-based use of this
herapy, further studies are needed to determine constraints
n the broader adoption of device therapies in HF patients.
eprint requests and correspondence: Dr. Adrian F. Hernandez,
uke Clinical Research Institute, 2400 Pratt Street, Durham,
orth Carolina 27710. E-mail: adrian.hernandez@duke.edu.
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